8-K: SeaStar Medical Reports Strong Q3 Revenue Growth, Clinical Trial Progress

SeaStar Medical announced a 247% increase in net revenue for Q3 2026 driven by QUELIMMUNE therapy adoption, alongside significant progress in its NEUTRALIZE-AKI pivotal trial.

Summary

• SeaStar Medical reported a 247% year-over-year increase in net revenue for the third quarter of 2026, reaching $635,000, primarily due to the adoption of its QUELIMMUNE therapy.
• The company has achieved nearly 75% enrollment in its NEUTRALIZE-AKI pivotal clinical trial for adult AKI patients, with enrollment completion now anticipated by mid-year 2027.
• Statistically significant higher survival rates for QUELIMMUNE-treated pediatric patients compared to a comparator cohort were presented at ASN Kidney Week 2026.
• The FDA has granted Breakthrough Device Designation for the SCD therapy for treating hyperinflammation in adult patients with sepsis or a septic condition, marking the seventh such designation.
• The company has submitted the first module of a modular premarket approval (PMA) application to the FDA for the SCD therapy in adult AKI patients.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with significant revenue growth and promising clinical trial updates, though a delay in trial completion introduces a minor concern.

Positives

• Net revenue increased by 247% to $635,000 in Q3 2026 compared to Q3 2025, driven by QUELIMMUNE therapy adoption.
• Gross profit margins remained strong at over 90%.
• Statistically significant higher survival rates were observed in QUELIMMUNE-treated pediatric patients versus comparator cohorts.
• No device-related adverse events were reported for QUELIMMUNE therapy in the SAVE Registry study.
• Enrollment in the NEUTRALIZE-AKI pivotal trial has reached nearly 75% (251 out of 339 patients).
• The FDA granted Breakthrough Device Designation for the SCD therapy for treating hyperinflammation in adult patients with sepsis or a septic condition.
• The company received dedicated ICD-10-PCS codes from CMS for the use of its SCD therapy in AKI patients requiring RRT.
• Nine-month net revenue for QUELIMMUNE more than doubled to $1.7 million, with expectations to exceed $2 million for the year.

Negatives

• The completion of enrollment for the NEUTRALIZE-AKI pivotal clinical trial has been extended to mid-year 2027.
• Net loss for Q3 2026 was $4.5 million, or $1.03 per share, compared to a net loss of $3.5 million, or $1.30 per share, in Q3 2025.
• Cash on hand decreased to $4.0 million at September 30, 2026, from $12.0 million at December 31, 2025.

Risks

• The risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates.
• The risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials.
• The risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so.
• The risk that SeaStar Medical may never achieve or sustain profitability.
• The risk that SeaStar Medical may not be able to secure additional financing on acceptable terms.
• The risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medicals products and services.
• The risk that SeaStar Medical is unable to secure or protect its intellectual property.

Future Outlook

The company anticipates exceeding its 2026 QUELIMMUNE revenue guidance of $2 million. Guidance for 2027 will be provided in early 2027. The company expects to file the final module of its PMA application approximately 9 months after completing enrollment in the NEUTRALIZE-AKI trial, with FDA review expected to take 180 days.

Management Comments

• "The strength of the QUELIMMUNE therapy adoption in this ultra-rare pediatric AKI market provides great promise for our pipeline indications, and we continue to build momentum in educating the critical care pediatric health care community."
• "The NEUTRALIZE-AKI pivotal clinical trial has enrolled nearly 75% of its intended 339 patients, and we have already submitted the first module of the premarket approval application to the FDA in hopes that our modular submission will speed this potential approval."
• "We are clearly disappointed to extend the timeline for completion of enrollment, but our highest priority is that the study is conducted to provide our SCD therapy the opportunity for an optimized outcome and ultimately be available to patients."
• "Our net revenue for QUELIMMUNE sales jumped significantly to over $630 thousand dollars in the quarter, increasing 247% compared to last years third quarter net revenue."
• "The FDA's decision now enables hospitals to employ the QUELIMMUNE therapy without the research infrastructure that the SAVE Registry demanded, which may increase availability for these critically ill pediatric patients."

Industry Context

StockSavvy.ai notes that SeaStar Medical's progress aligns with the growing focus on specialized treatments for critical care conditions like Acute Kidney Injury (AKI). The company's multiple Breakthrough Device Designations highlight a strategic approach to navigating regulatory pathways for novel therapies in areas with significant unmet needs, a trend observed across the medical device sector.

Stakeholder Impact

• Shareholders: Potential for increased value driven by revenue growth and progress in clinical trials, offset by the extended trial timeline and continued net losses.
• Patients: Improved access to QUELIMMUNE therapy due to fulfillment of FDA post-approval requirements, and potential future access to SCD therapy for adult AKI and sepsis.
• Healthcare Providers: Continued education and support for QUELIMMUNE adoption, and potential new treatment options with SCD therapy.
• Regulators (FDA, CMS): Ongoing engagement through PMA submissions and clinical trial data, with positive interactions highlighted by Breakthrough Device Designations and ICD-10-PCS codes.

Next Steps

• Continue to educate the critical care pediatric health care community on QUELIMMUNE therapy.
• Complete enrollment in the NEUTRALIZE-AKI pivotal clinical trial by mid-year 2027.
• Submit additional modules of the modular PMA application to the FDA.
• Continue to expand QUELIMMUNE adoption in top pediatric medical centers.
• Seek FDA approval for the SCD therapy for adult AKI and sepsis indications.

Key Dates

Recommendation

The company shows strong revenue growth and positive clinical developments, particularly with QUELIMMUNE. However, the extended timeline for the NEUTRALIZE-AKI trial and continued net losses warrant a cautious 'hold' rating. Investors should monitor trial progress and FDA submissions closely.

Keywords

QUELIMMUNE, SCD therapy, Acute Kidney Injury, AKI, Sepsis, Clinical Trial, Premarket Approval, FDA